search
Back to results

A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

Primary Purpose

Cryptosporidiosis, HIV Infections

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Spiramycin
Sponsored by
Rhone-Poulenc Rorer
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cryptosporidiosis focused on measuring Single-Blind Method, Spiramycin, AIDS-Related Opportunistic Infections, Injections, Intravenous, Cryptosporidiosis, Diarrhea, Drug Evaluation, Acquired Immunodeficiency Syndrome

Eligibility Criteria

13 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Concurrent Medication: Allowed: Vitamin supplements. Zidovudine (AZT) for patients previously taking AZT. However, dosing with spiramycin should be delayed until the dose of AZT has stabilized. The dose may be decreased for AZT-associated toxicity. Allowed for diarrhea: Loperamide hydrochloride capsules (2 mg) or loperamide hydrochloride liquid (1 mg/5 ml). Allowed for nausea: Sucralfate and metoclopramide hydrochloride. Allowed for vomiting: Prochlorperazine and trimethobenzamide hydrochloride. Allowed as prophylaxis for Pneumocystis carinii pneumonia (PCP): Aerosolized pentamidine. Patients must have: A diagnosis of AIDS according to the CDC. Chronic diarrhea. Presence of Cryptosporidium oocysts in stool specimen. Patients or a legally authorized representative must sign an informed consent form. Diet will be lactose free, maximum 7 g fat/day with unlimited calorie intake. Patients who require total parenteral nutrition will also be allowed oral intake. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Grade 4 (for hematologic) or Grade 3 (for all other) toxicity. Known sensitivity to macrolide antibiotics. Presence of other diarrhea-causing pathogens. Active opportunistic infection requiring systemic antimicrobial therapy. Toxicity grades according to NIAID toxicity scale for adults. Concurrent Medication: Excluded: Other investigational drugs. Cancer chemotherapy. Alpha interferon. Other immunomodulating agents. Other macrolide antibiotics. Trimethoprim / sulfamethoxazole. Ganciclovir. H2 blockers and AL-721. Medications known to cause gastrointestinal irritation or alteration of gastrointestinal motility or absorption should be avoided if possible. Zidovudine (AZT) therapy may not be initiated and the dose may not be increased during the study. Patients with the following are excluded: Grade 4 (for hematologic) or Grade 3 (for all other) toxicity. Known sensitivity to macrolide antibiotics. Presence of other diarrhea-causing pathogens. Active opportunistic infection requiring systemic antimicrobial therapy. Toxicity grades according to NIAID toxicity scale for adults. Prior Medication: Excluded within 7 days of study entry: Investigational drugs. Excluded within 14 days of study entry: Cancer chemotherapy. Alpha interferon. Other immunomodulating agents. Other macrolide antibiotics. Trimethoprim / sulfamethoxazole. Ganciclovir.

Sites / Locations

  • Kaiser Permanente Med Ctr
  • Johns Hopkins Univ School of Medicine
  • Univ of Massachusetts Med Ctr
  • Bellevue Hosp / New York Univ Med Ctr
  • Cornell Univ Med Ctr
  • Univ Hosp of Cleveland / Case Western Reserve Univ
  • Nelson Tebedo Community Clinic

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
June 23, 2005
Sponsor
Rhone-Poulenc Rorer
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT00000980
Brief Title
A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea
Official Title
Single-Blind Efficacy Evaluation of Intravenous Spiramycin in Subjects With AIDS-Related Cryptosporidial Diarrhea
Study Type
Interventional

2. Study Status

Record Verification Date
October 1990
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Rhone-Poulenc Rorer
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)

4. Oversight

5. Study Description

Brief Summary
To determine the safety and effectiveness of intravenous spiramycin in patients with AIDS-related cryptosporidial diarrhea. Spiramycin, a macrolide antibiotic, has been studied in the United States for the treatment of cryptosporidial diarrhea. Some reports suggest that spiramycin is useful in improving the symptoms of cryptosporidial diarrhea in some patients. Results of one study, however, showed no significant difference between spiramycin and placebo (inactive medication). A later study indicated that the absorption of spiramycin is significantly decreased when food is present. Thus, the results of the trial may have been due to poor absorption of spiramycin.
Detailed Description
Spiramycin, a macrolide antibiotic, has been studied in the United States for the treatment of cryptosporidial diarrhea. Some reports suggest that spiramycin is useful in improving the symptoms of cryptosporidial diarrhea in some patients. Results of one study, however, showed no significant difference between spiramycin and placebo (inactive medication). A later study indicated that the absorption of spiramycin is significantly decreased when food is present. Thus, the results of the trial may have been due to poor absorption of spiramycin. Patients are observed for 3 days to establish baseline conditions. They are informed that the treatment period is 21 days during which they receive 15 days of spiramycin and 6 consecutive days of placebo; they are not told which 6-day period they receive placebo. All patients receive 15 days of spiramycin. Patients who do not have a favorable response are treated with a higher dose of spiramycin for an additional 15 days. Responders at either dose are followed weekly for 4 weeks. Should a relapse occur, patients receive an additional 15 days of therapy, at the dose of spiramycin that initially produced a response, following reestablishment of a baseline with 6 days of placebo. Nonresponders to the higher dose are taken off the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cryptosporidiosis, HIV Infections
Keywords
Single-Blind Method, Spiramycin, AIDS-Related Opportunistic Infections, Injections, Intravenous, Cryptosporidiosis, Diarrhea, Drug Evaluation, Acquired Immunodeficiency Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Enrollment
25 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Spiramycin

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Vitamin supplements. Zidovudine (AZT) for patients previously taking AZT. However, dosing with spiramycin should be delayed until the dose of AZT has stabilized. The dose may be decreased for AZT-associated toxicity. Allowed for diarrhea: Loperamide hydrochloride capsules (2 mg) or loperamide hydrochloride liquid (1 mg/5 ml). Allowed for nausea: Sucralfate and metoclopramide hydrochloride. Allowed for vomiting: Prochlorperazine and trimethobenzamide hydrochloride. Allowed as prophylaxis for Pneumocystis carinii pneumonia (PCP): Aerosolized pentamidine. Patients must have: A diagnosis of AIDS according to the CDC. Chronic diarrhea. Presence of Cryptosporidium oocysts in stool specimen. Patients or a legally authorized representative must sign an informed consent form. Diet will be lactose free, maximum 7 g fat/day with unlimited calorie intake. Patients who require total parenteral nutrition will also be allowed oral intake. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Grade 4 (for hematologic) or Grade 3 (for all other) toxicity. Known sensitivity to macrolide antibiotics. Presence of other diarrhea-causing pathogens. Active opportunistic infection requiring systemic antimicrobial therapy. Toxicity grades according to NIAID toxicity scale for adults. Concurrent Medication: Excluded: Other investigational drugs. Cancer chemotherapy. Alpha interferon. Other immunomodulating agents. Other macrolide antibiotics. Trimethoprim / sulfamethoxazole. Ganciclovir. H2 blockers and AL-721. Medications known to cause gastrointestinal irritation or alteration of gastrointestinal motility or absorption should be avoided if possible. Zidovudine (AZT) therapy may not be initiated and the dose may not be increased during the study. Patients with the following are excluded: Grade 4 (for hematologic) or Grade 3 (for all other) toxicity. Known sensitivity to macrolide antibiotics. Presence of other diarrhea-causing pathogens. Active opportunistic infection requiring systemic antimicrobial therapy. Toxicity grades according to NIAID toxicity scale for adults. Prior Medication: Excluded within 7 days of study entry: Investigational drugs. Excluded within 14 days of study entry: Cancer chemotherapy. Alpha interferon. Other immunomodulating agents. Other macrolide antibiotics. Trimethoprim / sulfamethoxazole. Ganciclovir.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
R Soave
Official's Role
Study Chair
Facility Information:
Facility Name
Kaiser Permanente Med Ctr
City
San Diego
State/Province
California
ZIP/Postal Code
92120
Country
United States
Facility Name
Johns Hopkins Univ School of Medicine
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21205
Country
United States
Facility Name
Univ of Massachusetts Med Ctr
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States
Facility Name
Bellevue Hosp / New York Univ Med Ctr
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Cornell Univ Med Ctr
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Univ Hosp of Cleveland / Case Western Reserve Univ
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Nelson Tebedo Community Clinic
City
Dallas
State/Province
Texas
ZIP/Postal Code
75219
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

We'll reach out to this number within 24 hrs